des(1-3)IGF-1
| Clinical data | |
|---|---|
| Routes of administration | Intravenous administration |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C319H501N91O96S7 |
| Molar mass | 7371.48 g·mol−1 |
des(1-3)IGF-1 is a naturally occurring, endogenous protein, as well as drug, and truncated analogue of insulin-like growth factor 1 (IGF-1).[1][2][3][4] des(1-3)IGF-1 lacks the first three amino acids at the N-terminus of IGF-1 (for a total of 67 amino acids, relative to the 70 of IGF-1).[5] As a result of this difference, it has considerably reduced binding to the insulin-like growth factor-binding proteins (IGFBPs) and enhanced potency (about 10-fold in vivo) relative to IGF-1.[1][2][3][5]
The amino acid sequence of des(1-3)IGF-1 is TLCGAELVDA LQFVCGDRGF YFNKPTGYGS SSRRAPQTGI VDECCFRSCD LRRLEMYCAP LKPAKSA.[5]
See also
References
- ^ a b Gillespie C, Read LC, Bagley CJ, Ballard FJ (1990). "Enhanced potency of truncated insulin-like growth factor-I (des(1-3)IGF-I) relative to IGF-I in lit/lit mice". J. Endocrinol. 127 (3): 401–5. doi:10.1677/joe.0.1270401. PMID 2280209.
- ^ a b Simes JM, Wallace JC, Walton PE (1991). "The effects of insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I, a potent IGF analogue, on growth hormone and IGF-binding protein secretion from cultured rat anterior pituitary cells". J. Endocrinol. 130 (1): 93–9. doi:10.1677/joe.0.1300093. PMID 1715381.
- ^ a b Ballard FJ, Wallace JC, Francis GL, Read LC, Tomas FM (1996). "Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I". Int. J. Biochem. Cell Biol. 28 (10): 1085–7. doi:10.1016/1357-2725(96)00056-8. PMID 8930132.
- ^ Yamamoto H, Murphy LJ (1995). "Enzymatic conversion of IGF-I to des(1-3)IGF-I in rat serum and tissues: a further potential site of growth hormone regulation of IGF-I action". J. Endocrinol. 146 (1): 141–8. doi:10.1677/joe.0.1460141. PMID 7561610.
- ^ a b c Mario Thevis (13 December 2010). Mass Spectrometry in Sports Drug Testing: Characterization of Prohibited Substances and Doping Control Analytical Assays. John Wiley & Sons. pp. 252–. ISBN 978-1-118-03514-6.